Background: The prevalence of both chronic kidney disease (CKD) and aortic stenosis (AS) increase with age. Although baseline CKD is frequent in patients undergoing transcatheter aortic valve replacement (TAVR), its significance among women is largely unknown.
Methods: Women's INternational Transcatheter Aortic Valve Implantation (WIN-TAVI) is a multinational, prospective registry of women undergoing TAVR for severe AS. We included patients with available baseline estimated glomerular filtration rate (eGFR) and completed 1-year follow-up. Patients were categorized into three groups based on their eGFR: No CKD (normal kidney function to stage 2 CKD: eGFR ≥60 ml/min/1.73 m2 ); (b) mild CKD (stage 3a CKD: eGFR = 45-59 ml/min/1.73 m2 ); and (c) moderate/severe CKD (stage ≥3b CKD: eGFR <45 ml/min/1.73 m2 ). All events were adjudicated according to the Valve Academic Research Consortium (VARC)-2 criteria.
Result: Out of 852 women undergoing TAVR, 326 (38.3%) had no CKD, 225 (26.4%) had mild CKD, and 301 (35.3%) had moderate/severe CKD. Women with higher stage of CKD at baseline were more likely to have a history of hypertension, diabetes, atrial fibrillation, anemia, chronic lung disease, hemodialysis, prior percutaneous coronary intervention, and pacemaker implantation. After multivariate adjustment, moderate/severe CKD was associated with a greater risk of 1-year VARC-2 safety endpoints [hazard ratio (HR) 1.68, 95% confidence interval (CI): 1.10-2.60], all-cause death (HR 2.00, 95% CI: 1.03-3.90), and composite of death, myocardial infarction, stroke or life-threatening bleeding (HR 1.70, 95% CI: 1.04-2.76). There were no differences in 30-day and 1-year VARC-2 efficacy and 30-day VARC-2 safety outcomes.
Conclusion: CKD is associated with substantial and independent risk for mortality and morbidity at 1-year follow-up in women undergoing TAVR.
Keywords: WIN-TAVI registry; aortic stenosis; chronic kidney disease; transcatheter aortic valve replacement.
© 2020 Wiley Periodicals, Inc.
1-Year Clinical Outcomes in Women After Transcatheter Aortic Valve Replacement: Results From the First WIN-TAVI Registry.JACC Cardiovasc Interv. 2018 Jan 8;11(1):1-12. doi: 10.1016/j.jcin.2017.09.034. JACC Cardiovasc Interv. 2018. PMID: 29301640 Clinical Trial.
Acute and 30-Day Outcomes in Women After TAVR: Results From the WIN-TAVI (Women's INternational Transcatheter Aortic Valve Implantation) Real-World Registry.JACC Cardiovasc Interv. 2016 Aug 8;9(15):1589-600. doi: 10.1016/j.jcin.2016.05.015. JACC Cardiovasc Interv. 2016. PMID: 27491609 Clinical Trial.
Impact of Discharge Location After Transcatheter Aortic Valve Replacement on 1-Year Outcomes in Women: Results From the WIN-TAVI Registry.Can J Cardiol. 2019 Feb;35(2):199-207. doi: 10.1016/j.cjca.2018.11.035. Epub 2018 Dec 12. Can J Cardiol. 2019. PMID: 30760427 Clinical Trial.
Independent Risk Factors Contributing to Acute Kidney Injury According to Updated Valve Academic Research Consortium-2 Criteria After Transcatheter Aortic Valve Implantation: A Meta-analysis and Meta-regression of 13 Studies.J Cardiothorac Vasc Anesth. 2017 Jun;31(3):816-826. doi: 10.1053/j.jvca.2016.12.021. Epub 2016 Dec 21. J Cardiothorac Vasc Anesth. 2017. PMID: 28385646 Review.
Impact of renal dysfunction on mid-term outcome after transcatheter aortic valve implantation: a systematic review and meta-analysis.PLoS One. 2015 Mar 20;10(3):e0119817. doi: 10.1371/journal.pone.0119817. eCollection 2015. PLoS One. 2015. PMID: 25793780 Free PMC article. Review.
- Faggiano P, Antonini-Canterin F, Baldessin F, Lorusso R, D'Aloia A, Cas LD. Epidemiology and cardiovascular risk factors of aortic stenosis. Cardiovasc Ultrasound. 2006;4:27.
- Grigorios T, Stefanos D, Athanasios M, et al. Transcatheter versus surgical aortic valve replacement in severe, symptomatic aortic stenosis. J Geriatr Cardiol. 2018;15(1):76-85.
- Grover FL, Vemulapalli S, Carroll JD, et al. 2016 annual report of the Society of Thoracic Surgeons/American College of Cardiology Transcatheter Valve Therapy Registry. J Am Coll Cardiol. 2017;69(10):1215-1230.
- Durko AP, Osnabrugge RL, Van Mieghem NM, et al. Annual number of candidates for transcatheter aortic valve implantation per country: current estimates and future projections. Eur Heart J. 2018;39(28):2635-2642.
- Buchanan GL, Chieffo A, Montorfano M, et al. The role of sex on VARC outcomes following transcatheter aortic valve implantation with both Edwards SAPIEN and Medtronic CoreValve ReValving system (R) devices: the Milan registry. EuroIntervention. 2011;7(5):556-563.